表紙
市場調查報告書

磷脂肌醇-4,5-二磷酸鹽酯-3-激酶催化次單元Gamma Isoform:開發中產品分析

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 371940
出版日期 內容資訊 英文 127 Pages
訂單完成後即時交付
價格
Back to Top
磷脂肌醇-4,5-二磷酸鹽酯-3-激酶催化次單元Gamma Isoform:開發中產品分析 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 127 Pages
簡介

本報告提供以磷脂肌醇-4,5-二磷酸鹽酯-3-激酶催化次單元Gamma Isoform為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

磷脂肌醇-4,5-二磷酸鹽酯-3-激酶催化次單元Gamma Isoform 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Novartis AG
  • PIQUR Therapeutics AG
  • Rhizen Pharmaceuticals S.A.
  • Sphaera Pharma Pvt. Ltd.
  • 大正製藥集團
  • Vertex Pharmaceuticals Incorporated

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2204TDB

Summary

According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 - Pipeline Review, H2 2019'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform is an enzyme encoded by the PIK3CG gene. It plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. It is involved in immune, inflammatory and allergic responses. It modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. It regulates T-lymphocyte proliferation and cytokine production.

The report 'Phosphatidylinositol 4,5 Bisphosphate 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 13 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Hematological Disorders, Infectious Disease and Undisclosed which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Asthma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Pancreatic Cancer, Renal Cell Carcinoma, T-Cell Lymphomas, Triple-Negative Breast Cancer (TNBC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Allergic Asthma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cystic Fibrosis, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Natural Killer Cell Lymphomas, Neuroblastoma, Neutrophilia, Non-Small Cell Lung Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
  • The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Overview
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
  • Applied Therapeutics Inc
  • Arcus Biosciences Inc
  • AstraZeneca Plc
  • BioMed Valley Discoveries Inc
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd.
  • Hutchison MediPharma Ltd
  • Infinity Pharmaceuticals Inc
  • Kither Biotech Srl
  • Novartis AG
  • PIQUR Therapeutics AG
  • Rhizen Pharmaceuticals SA
  • Sichuan Sinovation Bio-technology Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Sphaera Pharma Pte Ltd
  • Verastem Inc
  • Vertex Pharmaceuticals Inc
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
  • AB-610 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZD-8154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bimiralisib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BVD-723 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CL-27 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • duvelisib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IPI-549 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KIT-2014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PQR-514 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SF-2523 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PI3K Delta and PI3K Gamma for Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PI3K Gamma for Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit PIK3CG for Chronic Obstructive Pulmonary Disease and Neutrophilia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PIK3CA and PIK3CG for Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PIK3CD and PIK3CG for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SN-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPR-965 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tenalisib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WX-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
  • Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 07, 2019: Verastem oncology presents phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral T-Cell lymphoma at the american society of hematology 2019 annual meeting
  • Nov 25, 2019: Verastem Oncology announces submission of a marketing authorization application to the European Medicines Agency for COPIKTRA (duvelisib)
  • Nov 06, 2019: Verastem Oncology to phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral t-cell lymphoma at the American Society of Hematology 2019 Annual Meeting
  • Oct 23, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Lymphoma & Myeloma 2019 International Congress
  • Oct 07, 2019: Verastem Oncology announces dosing of first patient in Vakult Honsha Japanese bridging study evaluating Copiktra (Duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Oct 03, 2019: Verastem Oncology receives Orphan Drug Designation from FDA for COPIKTRA for the treatment of T-Cell Lymphoma
  • Oct 03, 2019: Verastem Oncology presents new preclinical Duvelisib data at the 5th International Conference on new concepts in lymphoid malignancies
  • Sep 25, 2019: AstraZeneca to present AZD8154 data at ERS International Congress
  • Sep 20, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia
  • Sep 04, 2019: Infinity Pharmaceuticals announces the initiation of two clinical trials evaluating IPI-549 in novel Triple Combination Therapies for the treatment of Solid Tumors
  • Sep 03, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Society of Hematologic Oncology 2019 Annual Meeting
  • Aug 22, 2019: Infinity Pharmaceuticals announces transition of Samuel Agresta, M.D., from chief medical officer to board of directors
  • Jun 21, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data in peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma
  • Jun 17, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data at the European Hematology Association 2019 Annual Meeting
  • May 15, 2019: Verastem Oncology to present new COPIKTRA (Duvelisib) dose modification data from patients treated in the phase 3 DUO study
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Applied Therapeutics Inc, H2 2019
  • Pipeline by Arcus Biosciences Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by BioMed Valley Discoveries Inc, H2 2019
  • Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H2 2019
  • Pipeline by Hutchison MediPharma Ltd, H2 2019
  • Pipeline by Infinity Pharmaceuticals Inc, H2 2019
  • Pipeline by Kither Biotech Srl, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by PIQUR Therapeutics AG, H2 2019
  • Pipeline by Rhizen Pharmaceuticals SA, H2 2019
  • Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H2 2019
  • Pipeline by SignalRx Pharmaceuticals Inc, H2 2019
  • Pipeline by Sphaera Pharma Pte Ltd, H2 2019
  • Pipeline by Verastem Inc, H2 2019
  • Pipeline by Vertex Pharmaceuticals Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top